AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38483412 — intervention group
Group type: COMPARATOR
Intervention: COPORT (66.6 Gy in 37 fractions)
Number of subjects: 296
Study 38483418 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-POAF within the first 90 postoperative days
Number of subjects: 133
Study 38483418 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-POAF after the first 90 postoperative days
Number of subjects: 133
Study 38483418 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative variables for predicting late-POAF
Number of subjects: 133
Study 38483418 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of advanced AF substrate (increased right atrial volumes)
Number of subjects: 133
Study 38483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who reported having a clear plan, agreed with the plan, and intended to follow the plan.
Number of subjects: 2555
Study 38483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who reported plans related to follow-up with the primary care provider.
Number of subjects: 2555
Study 38483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who reported plans to initiate or adjust medications.
Number of subjects: 2555
Study 38483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who reported plans for a specialist visit.
Number of subjects: 2555
Study 38483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients indicating intent to follow their plan.
Number of subjects: 2555
Study 38483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who assessed their plan as clear, agreed with it, and were willing to follow it.
Number of subjects: 2555
Study 38483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients whose plans involved lifestyle changes.
Number of subjects: 2555
Study 38483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for completely following the plan.
Number of subjects: 2555
Study 38483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for not following the plan.
Number of subjects: 2555
Study 38483463 — intervention group
Group type: EXPERIMENTAL
Intervention: e-SBI (Electronic Screening and Brief Intervention)
Number of subjects: 200
Study 38483463 — intervention group
Group type: COMPARATOR
Intervention: Screening only
Number of subjects: 200
Study 38483469 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (n=102)
Number of subjects: 204
Study 38483469 — intervention group
Group type: COMPARATOR
Intervention: Control stretching and strengthening intervention (n=102)
Number of subjects: 204
Study 38483522 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrator disclosure
Number of subjects: 0
Study 38483522 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (BMI) techniques
Number of subjects: 0
Study 38483522 — intervention group
Group type: EXPERIMENTAL
Intervention: High empathy condition
Number of subjects: 0
Study 38483522 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI techniques
Number of subjects: 0
Study 38483522 — intervention group
Group type: COMPARATOR
Intervention: Neither narrator disclosure nor BMI techniques
Number of subjects: 0
Study 38483534 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) transfusion with high antibody levels (upper 30% of study donors' antibody levels)
Number of subjects: 17
Study 38483534 — intervention group
Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 17
Study 38483543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester (KME) ingestion
Number of subjects: 10
Study 38483543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 38483611 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab (6.0 mg up to every 16 weeks after 4 initial Q4W doses)
Number of subjects: 133
Study 38483611 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept (2.0 mg Q8W after 3 initial Q4W doses)
Number of subjects: 133
Study 38483611 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab
Number of subjects: 133
Study 38483611 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 133
Study 38483633 — intervention group
Group type: COMPARATOR
Intervention: Modified Balloons (MB)
Number of subjects: 200
Study 38483633 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy (RA)
Number of subjects: 200
Study 38483732 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative IL8 levels
Number of subjects: 240
Study 38483732 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative IL18 levels
Number of subjects: 240
Study 38483732 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative IL concentrations
Number of subjects: 240
Study 38483732 — intervention group
Group type: EXPERIMENTAL
Intervention: NBM volume
Number of subjects: 240
Study 38483732 — intervention group
Group type: EXPERIMENTAL
Intervention: NBM atrophy
Number of subjects: 240
Study 38483732 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic value of preoperative IL concentrations
Number of subjects: 240
Study 38483776 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h replacement interval
Number of subjects: 1240
Study 38483776 — intervention group
Group type: COMPARATOR
Intervention: 96-h replacement interval
Number of subjects: 1240
Study 38483782 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 100 mg plus Pembrolizumab 200 mg
Number of subjects: 32
Study 38483782 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 125 mg plus Pembrolizumab 200 mg
Number of subjects: 32
Study 38483782 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (various doses) plus Pembrolizumab
Number of subjects: 32
Study 38483782 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib plus Pembrolizumab
Number of subjects: 32
Study 38483869 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred multicomponent care transition support
Number of subjects: 0
Study 38483940 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (20mg/70kg and 30mg/70kg)
Number of subjects: 24
Study 38484130 — intervention group
Group type: EXPERIMENTAL
Intervention: c-Jun N-Terminal Kinase Inhibitor
Number of subjects: 0
Study 38484130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38484209 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NAT)
Number of subjects: 177
Study 38484209 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted agents
Number of subjects: 177
Study 38484239 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol preoperatively for 7 days
Number of subjects: 0
Study 38484251 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/5 injection
Number of subjects: 108
Study 38484251 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/10 injection
Number of subjects: 108
Study 38484432 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg once daily
Number of subjects: 156
Study 38484432 — intervention group
Group type: COMPARATOR
Intervention: Prior imatinib
Number of subjects: 156
Study 38484432 — intervention group
Group type: COMPARATOR
Intervention: Prior dasatinib
Number of subjects: 156
Study 38484432 — intervention group
Group type: COMPARATOR
Intervention: Prior nilotinib
Number of subjects: 156
Study 38484756 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended postnatal prophylaxis with lamivudine syrup twice per day for 12 months or 1 month after breastfeeding discontinuation, initiated based on maternal viral load measured using Xpert HIV viral load assay.
Number of subjects: 1506
Study 38484756 — intervention group
Group type: COMPARATOR
Intervention: Control group following national guidelines for prevention of postnatal transmission of HIV.
Number of subjects: 1506
Study 38484756 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control) regarding HIV-free survival and serious adverse events.
Number of subjects: 1506
Study 38484795 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with ADHD
Number of subjects: 62
Study 38484795 — intervention group
Group type: COMPARATOR
Intervention: Non-psychiatric controls
Number of subjects: 62
Study 38484853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dry needling (DN) and spinal manipulative therapy (SMT)
Number of subjects: 96
Study 38484853 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN) only
Number of subjects: 96
Study 38484853 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) only
Number of subjects: 96
Study 38484853 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study 38484976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1.9 g/d n-3 PUFAs)
Number of subjects: 40
Study 38484976 — intervention group
Group type: COMPARATOR
Intervention: Control oil (high-oleic safflower oil)
Number of subjects: 40
Study 38485054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide (40 mg)
Number of subjects: 65
Study 38485054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 38485184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) administered every 2 weeks until disease progression, unacceptable toxicity, or for 24 months
Number of subjects: 48
Study 38485184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 48
Study 38485188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 41
Study 38485189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks (2 mg/kg up to 200 mg for pediatric patients)
Number of subjects: 976
Study 38485189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 976
Study 38485189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 976
Study 38485190 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus SOC (5-fluorouracil/leucovorin/oxaliplatin/bevacizumab)
Number of subjects: 310
Study 38485190 — intervention group
Group type: COMPARATOR
Intervention: SOC (5-fluorouracil/leucovorin/oxaliplatin/bevacizumab)
Number of subjects: 310
Study 38485210 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (fixed-dose combination therapy including two antihypertensive agents, a statin, and aspirin)
Number of subjects: 4415
Study 38485210 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological intervention (educational training on healthy lifestyle)
Number of subjects: 4415
Study 38485313 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL 0.5% bupivacaine
Number of subjects: 152
Study 38485313 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 152
Study 38485472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) during DLT intubation
Number of subjects: 112
Study 38485472 — intervention group
Group type: COMPARATOR
Intervention: Traditional mask transnasal oxygen
Number of subjects: 112
Study 38485473 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 or more periods of at least 7 days' smoking abstinence during pregnancy
Number of subjects: 407
Study 38485473 — intervention group
Group type: COMPARATOR
Intervention: No abstinence periods
Number of subjects: 407
Study 38485473 — intervention group
Group type: COMPARATOR
Intervention: Reduction of smoking intensity by at least 50%
Number of subjects: 407
Study 38485473 — intervention group
Group type: COMPARATOR
Intervention: Reduction of cigarette consumption
Number of subjects: 407
Study 38485475 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multicomponent lifestyle intervention (the ADA programme)
Number of subjects: 0
Study 38485475 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38485487 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (NO)
Number of subjects: 0
Study 38485487 — intervention group
Group type: COMPARATOR
Intervention: Control (no inhaled NO)
Number of subjects: 0
Study 38485490 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid replacement therapy (ORT) with benzodiazepine (BZD) coprescription
Number of subjects: 46899
Study 38485490 — intervention group
Group type: COMPARATOR
Intervention: Opioid replacement therapy (ORT) alone
Number of subjects: 46899
Study 38485651 — intervention group
Group type: COMPARATOR
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 60
Study 38485651 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen Matrix (CMX)
Number of subjects: 60
Study 38485862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand Eczema Symptom Diary (HESD)
Number of subjects: 280
Study 38485863 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 1979
Study 38485863 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 1979
Study 38485863 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 1979
Study 38485863 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 1979
Study 38486069 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based interventions that increased vaccinations in prior field work (RCT1, NCT05586204)
Number of subjects: 314824
Study 38486069 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based interventions that elevated vaccination intentions in an online study (RCT2, NCT05586178)
Number of subjects: 314824
Study 38486069 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based interventions favoured by scientists and non-experts (RCT3, NCT05586165)
Number of subjects: 314824
Study 38486069 — intervention group
Group type: COMPARATOR
Intervention: Encouraging the bundling of COVID-19 boosters and flu shots
Number of subjects: 314824
Study 38486069 — intervention group
Group type: COMPARATOR
Intervention: Addressing misconceptions about COVID-19 boosters
Number of subjects: 314824
Study 38486179 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based follow-up with individual treatment plan, computer tablets, and home telemonitoring devices.
Number of subjects: 126
Study 38486179 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based follow-up
Number of subjects: 126
Study 38486192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT)
Number of subjects: 68
Study 38486278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition program delivered to mothers' groups
Number of subjects: 0
Study 38486278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled nutrition and parenting program delivered to mothers' groups
Number of subjects: 0
Study 38486278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition program delivered to mothers' and fathers' groups
Number of subjects: 0
Study 38486278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled nutrition and parenting program delivered to mothers' and fathers' groups
Number of subjects: 0
Study 38486278 — intervention group
Group type: COMPARATOR
Intervention: Standard of care health services (control)
Number of subjects: 0
Study 38486304 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cohort
Number of subjects: 778
Study 38486304 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 cohort
Number of subjects: 778
Study 38486359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task exergaming telerehabilitation (n=20)
Number of subjects: 39
Study 38486359 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (AEx) only (n=11)
Number of subjects: 39
Study 38486359 — intervention group
Group type: COMPARATOR
Intervention: Attention control (stretching) (n=8)
Number of subjects: 39
Study 38486776 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose primary series of ancestral strain vaccine
Number of subjects: 0
Study 38486776 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent Beta variant booster vaccine
Number of subjects: 0
Study 38486776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancestral or variant strain booster vaccine
Number of subjects: 0
Study 38486810 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing with result disclosure and genetic counseling
Number of subjects: 14
Study 38487037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 53
Study 38487037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 38487528 — intervention group
Group type: EXPERIMENTAL
Intervention: SON-1010 at 100 ng/kg or higher
Number of subjects: 8
Study 38487528 — intervention group
Group type: EXPERIMENTAL
Intervention: SON-1010 at 50-300 ng/kg
Number of subjects: 8
Study 38487528 — intervention group
Group type: EXPERIMENTAL
Intervention: SON-1010
Number of subjects: 8
Study 38487528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 38487573 — intervention group
Group type: EXPERIMENTAL
Intervention: D-HOMES intervention (one-on-one, 3 month coaching intervention)
Number of subjects: 36
Study 38487573 — intervention group
Group type: EXPERIMENTAL
Intervention: D-HOMES intervention
Number of subjects: 36
Study 38487573 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC; brief diabetes education session and routine care)
Number of subjects: 36
Study 38487573 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 36
Study 38487818 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration (mean 11 months, IQR 7-14 months)
Number of subjects: 76
Study 38487818 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration in women with GDM history
Number of subjects: 76
Study 38487818 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration
Number of subjects: 76
Study 38488039 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix
Number of subjects: 0
Study 38488139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 38488139 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 0
Study 38488388 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to second-generation antipsychotics
Number of subjects: 0
Study 38488429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Number of subjects: 49
Study 38488429 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 38488572 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38488780 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison intervention
Number of subjects: 38235
Study 38488780 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines intervention
Number of subjects: 38235
Study 38488780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38235
Study 38488827 — intervention group
Group type: EXPERIMENTAL
Intervention: MS CATCH (intervention used during clinician visits)
Number of subjects: 50
Study 38488827 — intervention group
Group type: COMPARATOR
Intervention: No MS CATCH (control group)
Number of subjects: 50
Study 38488975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks (Q4W)
Number of subjects: 698
Study 38488975 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 698
Study 38488975 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab 100 mg every 8 weeks (Q8W)
Number of subjects: 698
Study 38488976 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 0
Study 38488976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) or sulfasalazine
Number of subjects: 0
Study 38489057 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 3% Gel
Number of subjects: 0
Study 38489057 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38489060 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept treatment
Number of subjects: 0
Study 38489063 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap + xenogeneic collagen matrix (test group)
Number of subjects: 20
Study 38489117 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 30 μg
Number of subjects: 1485
Study 38489117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1485
Study 38489117 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 10 μg (5- to 11-year-olds)
Number of subjects: 1485
Study 38489117 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 30 μg (12- to 15-year-olds)
Number of subjects: 1485
Study 38489117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5- to 11-year-olds)
Number of subjects: 1485
Study 38489119 — intervention group
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Number of subjects: 0
Study 38489119 — intervention group
Group type: COMPARATOR
Intervention: E/C/F/TAF
Number of subjects: 0
Study 38489173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort enrolled in Special Care Unit for BPSD (SCU-B)
Number of subjects: 508
Study 38489173 — intervention group
Group type: COMPARATOR
Intervention: Cohort not enrolled in Special Care Unit for BPSD (non-SCU-B)
Number of subjects: 508
Study 38489173 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 508
Study 38489173 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education level increase
Number of subjects: 508
Study 38489173 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric Inventory total increase
Number of subjects: 508
Study 38489173 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Mini-Mental State Examination
Number of subjects: 508
Study 38489173 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (females versus males)
Number of subjects: 508
Study 38489186 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAS-Cog 12
Number of subjects: 0
Study 38489186 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCS-ADL
Number of subjects: 0
Study 38489186 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL-AD
Number of subjects: 0
Study 38489236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sema7A
Number of subjects: 0
Study 38489236 — intervention group
Group type: COMPARATOR
Intervention: Sema7A-/- animals
Number of subjects: 0
Study 38489346 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers-only
Number of subjects: 390
Study 38489346 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents-combined
Number of subjects: 390